C. S. Lam

发表

Inter‐relationships between cardiovascular, renal and metabolic diseases: Underlying evidence and implications for integrated interdisciplinary care and management

P. Fenici, J. Spaak, N. Kanumilli, 2024, Diabetes, obesity & metabolism.

Applying the UTAUT2 framework to patients’ attitudes toward healthcare task shifting with artificial intelligence

C. Chandramouli, Fei Huang, Weiting Huang, 2024, BMC health services research.

Statins and risks of dementia among patients with heart failure: a population-based retrospective cohort study in Hong Kong

K. Yiu, Mei-Zhen Wu, Y. Tse, 2024, The Lancet regional health. Western Pacific.

Applications of SGLT2 inhibitors beyond glycaemic control.

M. Jardine, J. Dawson, S. Raichand, 2024, Nature reviews. Nephrology.

Cardiovascular and renal outcomes with varying degrees of kidney disease in high‐risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE‐O trial

H. Gerstein, R. Pratley, C. Ramasundarahettige, 2023, Diabetes, obesity & metabolism.

Longitudinal NT‐proBNP: Associations With Echocardiographic Changes and Outcomes in Heart Failure

W. Tay, O. Liew, W. Ouwerkerk, 2024, Journal of the American Heart Association.

Sex-related similarities and differences in responses to heart failure therapies.

A. Voors, Hailun Qin, Janice Y Chyou, 2024, Nature reviews. Cardiology.

Glycated Hemoglobin Variability Is Associated With Adverse Outcomes in Patients With Heart Failure Irrespective of Diabetic Status

Fang Wang, Mei-Zhen Wu, Y. Tse, 2024, Journal of the American Heart Association.

Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design.

P. Kowey, P. Steg, Sneha S. Jain, 2024, American heart journal.